Table 3.
Outcomes and adverse events of patients with high-dose daptomycin therapy
| Characteristic | Total (n = 67) |
Daptomycin dose (mg/kg) |
|
|
|---|---|---|---|---|
| ≤ 8 (n = 41) | > 8 (n = 26) | P value | ||
| 14-day mortality |
11 (16.4%) |
6 (14.6%) |
5 (19.2%) |
0.74 |
| 28-day mortality |
24 (35.8%) |
13 (31.7%) |
11 (42.3%) |
0.44 |
| In-hospital mortality |
33 (49.3%) |
20 (48.8%) |
13 (50.0%) |
0.92 |
| ICU patients (n = 41) |
28 (68.3%) |
17/24 (70.8%) |
11/17 (64.7%) |
0.74 |
| Infection-related death |
9 (13.4%) |
5 (12.2%) |
4 (15.4%) |
0.73 |
| ICU patients (n = 41) |
7 (17.1%) |
4/24 (16.7%) |
3/17 (17.6%) |
>0.99 |
| Clinical success |
52 (77.6%) |
32 (78.0%) |
20 (76.9%) |
0.91 |
| All bacteremia (n = 54) |
43 (79.6%) |
27/32 (84.4%) |
16/22 (72.7%) |
0.32 |
| MRSA (n = 38) |
28 (73.7%) |
18/23 (78.3%) |
10/15 (66.7%) |
0.47 |
| Vancomycin MIC ≥ 2 μg/mL (n = 24) |
19 (79.2%) |
13/14 (92.9%) |
6/10 (60%) |
0.12 |
| VRE (n = 18) |
12 (66.7%) |
7/12 (58.3%) |
5/6 (83.3%) |
0.60 |
| Endocarditis (n = 11) |
6 (54.5%) |
2/3 (66.7%) |
4/8 (50.0%) |
>0.99 |
| Catheter-related bacteremia (n = 16) |
15 (93.8%) |
10/11 (90.9%) |
5/5 (100%) |
0.59 |
| cSSTI (n = 16) |
14 (87.5%) |
7/9 (77.8%) |
7/7 (100%) |
0.48 |
| Bone & joint infection (n = 9) |
6 (66.7%) |
4/6 (66.7%) |
2/3 (66.7%) |
>0.99 |
| Microbiological success |
55 (82.1%) |
36 (87.8%) |
19 (73.1%) |
0.19 |
| Adverse events |
|
|
|
|
| Cytopenia |
47 (70.2%) |
28 (68.3%) |
19 (73.1%) |
0.68 |
| Renal dysfunction |
14 (20.9%) |
8 (19.5%) |
6 (23.1%) |
0.73 |
| Elevated AST/ALT |
20/66 (30.3%) |
12/41 (29.3%) |
8/25 (32.0%) |
0.82 |
| CPK elevations |
|
|
|
|
| Any |
16 (29.2%) |
7/37 (18.9%) |
9/24 (37.5%) |
0.11 |
| By definition | 4/61 (6.6%) | 0/37 (0%) | 4/24 (16.7%) | 0.02 |
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CPK, creatine phosphokinase; cSSTI, complicated skin and soft-tissue infection; MIC, minimum inhibitory concentration; MRSA, methicillin-resistant S. aureus; VRE, vancomycin-resistant enterococci.